Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients

Summary The peri- and postsurgical thromboembolic prophylaxis with low molecular weight heparins is a well established therapy regimen, but the optimum duration of prophylaxis after surgery still remains uncertain. A few studies have pointed to the fact that the thromboembolic risk of high-risk patients persists longer than the in-hospital period correlating with respective hypercoagulatory conditions. The aim of the present study was to test if a prolongation of thromboprophylaxis with the low molecular weight heparin Certoparin further reduces the rate of thromboembolism in high-risk patients after orthopedic surgery. The “Long-term Thromboprophylaxis”-Study was a multicenter, randomized, double-blind, placebo-controlled trial. 360 patients who underwent endoprothetic joint replacement or osteosyn-thesis of the lower limb were initially enrolled, all of them received prophylactically 3000 U anti-Xa of Certoparin once daily for 14 days followed by randomization to prolonged Certoparin application or to placebo up to day 42. Patients were screened for deep vein thrombosis by sonography every week. Coagulation markers (fibrin monomers and D-dimers) were determined during the course of the study. Venous thromboembolism during the prolongation period was observed in 18 patients receiving placebo versus 8 patients of the prolonged Certoparin group (12.1% versus 5.0%, intention-to-treat sample). The analysis revealed a statistically significant difference in favor of Certoparin (p=0.020), which was confirmed by per-protocol analysis (14.2% versus 5.5%, p=0.012). The differences remained significant, if analyses considered only clinically symptomatic thromboembolic events (p=0.040). Patients who developed a thrombosis showed a strong increase of coagulation markers as compared to patients without subsequent thrombosis. The respective differentiation started around 18 days before diagnosis of thrombosis. Only one minor bleeding complication was observed during prolonged Certoparin prophylaxis. The present study shows that patients after joint replacement or osteosynthesis of the lower extremities have a persisting risk to develop thromboembolic complications beyond the routine duration of thromboprophylaxis. Extended prophylaxis with Certoparin resulted in a significantly lower rate of thromboembolism and should be strongly recommended.

[1]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison , 2002, The Lancet.

[2]  J. Skinner,et al.  CURRENT CONCEPTS IN VENOUS THROMBOEMBOLISM AND MAJOR LOWER LIMB ORTHOPAEDIC SURGERY , 2002, International journal of clinical practice.

[3]  J. Douketis,et al.  Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials , 2001, The Lancet.

[4]  S. Ziegler,et al.  Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. , 2001, Thrombosis research.

[5]  A. Cohen,et al.  Extended Thromboprophylaxis with Low Molecular Weight Heparin Reduces Symptomatic Venous Thromboembolism following Lower Limb Arthroplasty - a Meta-analysis , 2001, Thrombosis and Haemostasis.

[6]  T. Whitsett,et al.  Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement , 2001, The Journal of bone and joint surgery. American volume.

[7]  G. Kolb,et al.  The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. , 2000, Thrombosis research.

[8]  Eter,et al.  A COMPARISON OF RECOMBINANT HIRUDIN WITH A LOW-MOLECULAR-WEIGHT HEPARIN TO PREVENT THROMBOEMBOLIC COMPLICATIONS AFTER TOTAL HIP REPLACEMENT , 2000 .

[9]  G. Lowe,et al.  Prediction of Deep Vein Thrombosis after Elective Hip Replacement Surgery by Preoperative Clinical and Haemostatic Variables: The ECAT DVT Study , 1999, Thrombosis and Haemostasis.

[10]  E. Ohman,et al.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1998, Chest.

[11]  S. Aaron,et al.  Low Molecular Weight Heparin Decreases Proximal and Distal Deep Venous Thrombosis Following Total Knee Arthroplasty , 1998, Thrombosis and Haemostasis.

[12]  M. Math,et al.  Noninvasive Diagnosis of Deep Venous Thrombosis , 1998, Annals of Internal Medicine.

[13]  H. Ostermann.  Low molecular weight heparins , 1998, Der Internist.

[14]  A. Nielsen,et al.  Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. , 1998, Thrombosis research.

[15]  H. Arnesen,et al.  Prolonged Thromboprophylaxis Following Hip Replacement Surgery – Results of a Double-blind, Prospective, Randomised, Placebo-controlled Study with Dalteparin (Fragmin®) , 1997, Thrombosis and Haemostasis.

[16]  A. Planès,et al.  Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo , 1996, The Lancet.

[17]  H. Arnesen,et al.  Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. , 1995, Thrombosis research.

[18]  P. Bauer,et al.  Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.

[19]  J. Boissel,et al.  Low molecular weight heparin in prevention of perioperative thrombosis. , 1992, BMJ.

[20]  H. Büller,et al.  Detection of deep vein thrombosis with impedance plethysmography and real-time compression ultrasonography in hospitalized patients. , 1992, Archives of internal medicine.

[21]  J. Vandenbroucke,et al.  Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis , 1992, The Lancet.

[22]  O. Huber,et al.  Postoperative pulmonary embolism after hospital discharge. An underestimated risk. , 1992, Archives of surgery.

[23]  J. G. Sharnoff.  Prevention of thromboembolism. , 1963 .